Latest Regulatory News

Cyclopharm Limited is accelerating its US market push for Technegas with a A$16 million capital raise following a record 2025 sales performance. The company aims to expand its US installations and advance new clinical applications beyond pulmonary embolism.

PYC Therapeutics has successfully closed a $537 million institutional placement and entitlement offer, positioning the company to raise at least $600 million to advance its RNA-based therapies targeting genetic diseases.

Island Pharmaceuticals has raised $9 million to advance its antiviral drug Galidesivir through the FDA’s Animal Rule pathway, targeting inclusion in the US Strategic National Stockpile for biodefense viruses.

Bellavista Resources has successfully raised A$35 million through a two-tranche placement to fund its strategic acquisition and exploration plans in Canada and Australia.

Island Pharmaceuticals secures FDA confirmation on Galidesivir’s development under the Animal Rule, unlocking a streamlined two-stage approval process and significant commercial incentives.

DataWorks has secured a significant contract extension with iGaming Ontario, adding over C$12.5 million to its Centralised Self-Exclusion program services. This move strengthens its recurring revenue and solidifies its RegTech division’s profitability.

Celsius Resources has voluntarily suspended its shares on the ASX pending a Supreme Court ruling on the validity of its former auditor's 2011 resignation. The suspension will last until the court decision or 9 February 2026, whichever comes first.

Viking Mines has reported outstanding tungsten assay results up to 14.7% WO3 from surface sampling at its Nevada Linka Project, validating historical high-grade mineralisation across multiple sites. These findings underpin the company’s strategic push towards drilling and development in the US tungsten sector.

Nova Minerals plans to redomicile to the United States following the loss of its foreign private issuer status, while acquiring full ownership of its Estelle Gold and Critical Minerals Project and appointing a US-based CFO.

Dalaroo Metals has mobilised its geological team to progress the Bongouanoa Gold Project in Côte d’Ivoire toward drill-ready status, leveraging promising historical gold intercepts and systematic fieldwork. The company is preparing for aircore and diamond drilling programs pending regulatory approvals.

Vitrafy Life Sciences has delivered key milestones in the first half of FY26, including a strategic partnership with IMV Technologies and progress in clinical studies, while maintaining a strong cash position to support its U.S. expansion and product launches.

5E Advanced Materials has successfully closed an oversubscribed US$36 million public offering, positioning itself to advance its boron operations and finalise key commercial contracts.